Immunoproliferative Disorders  >>  Phase 3
Welcome,         Profile    Billing    Logout  

11 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Immunoproliferative Disorders
NCT02449278: The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

Recruiting
3
120
RoW
Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone
Wuhan University
Diffuse Large B-cell Lymphoma
10/19
10/25
NCT02449252: Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma

Recruiting
3
120
RoW
Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone
Wuhan University
Follicular Lymphoma
10/19
10/25
NCT02449265: Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma

Recruiting
3
160
RoW
Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone
Wuhan University
Diffuse Large B-cell Lymphoma
10/19
10/25
WUCC-NHL02, NCT02438501: Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma

Recruiting
3
166
RoW
Low-dose involved-field radiotherapy, Involved-field radiotherapy
Di Deng
Recurrent Follicular Lymphoma
10/19
10/25
NCT03016000: Thalidomide Maintenance Treatment in DLBCL

Recruiting
3
226
RoW
Thalidomide, Thalomid, Observation
Nanfang Hospital of Southern Medical University
Lymphoma, Large B-Cell, Diffuse
12/19
12/23
NCT02842931: R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis

Recruiting
3
300
RoW
R-DA-EPOCH-21, R-DA-EPOCH-21 + auto-SCT, R-mNHL-BFM-90, R-mNHL-BFM-90 + auto-SCT
National Research Center for Hematology, Russia, National Research Center for Hematology
Diffuse Large B-Cell Lymphoma
02/20
02/23
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
Myeloma XI, NCT01554852 / 2009-010956-93: Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients

Checkmark From P3 Myeloma XI trial in NDDM at ASH 2016
Dec 2016 - Dec 2016: From P3 Myeloma XI trial in NDDM at ASH 2016
Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Active, not recruiting
3
4420
Europe
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Revlimid (lenalidomide), Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen, Kyprolis (carfilzomib), Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen, Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen, Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen, Velcade (bortezomib), Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance, Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance, Zolinza (vorinostat), High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)
University of Leeds, Celgene, Merck Sharp & Dohme LLC, Amgen
Multiple Myeloma
12/21
12/22
DOBL, NCT02964858: Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

Recruiting
3
840
RoW
Standard Arm, Experimental Arm
Tata Memorial Hospital
NonHodgkin Lymphoma
11/22
06/23
CAALL-F01, NCT02716233: A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents

Recruiting
3
1578
Europe
pegaspargase 1250 IU/m2 x 2, ONCASPAR 1250 IU/m2 x 2, pegaspargase 2500 IU/m2 x 1, ONCASPAR 2500 IU/m2 x 1
Assistance Publique - Hôpitaux de Paris, Shire
Acute Lymphoblastic Leukemia
04/26
04/26
NCT01595048 / 2010-019224-31: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia

Active, not recruiting
2/3
640
US, Canada, RoW
Rituximab, MOAB IDEC-C2B8, Prednisone, Etoposide, Lastet, Doxorubicin Hydrochloride, Cytarabine, CHX-3311, U-19920, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Methotrexate, Methylprednisolone, MePRDL, Leucovorin Calcium, CF, Therapeutic Hydrocortisone, Aeroseb-HC, Cetacort, HC, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma
12/20
12/20

Download Options